ORGO vs SMTI
ORGO: A regenerative medicine company providing advanced wound care and surgical tissue-engineered products to improve healing outcomes in patients with chronic and acute wounds. SMTI: Sanara MedTech is a surgical products company focused on soft tissue repair and bone fusion technologies, currently pending acquisition by MiMedx Group.
Side-by-side fundamentals
| Metric | ORGO | SMTI | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $1.28 | $35.05 | |
| Market cap | $165M | $322M | |
| Net margin FY2025, SEC XBRL | +6.6% | -36.4% | ORGO higher |
| Gross margin | +76.0% | +92.7% | SMTI higher |
| Operating margin FY2025, SEC XBRL | +7.9% | +7.1% | ORGO higher |
| ROE FY2025, SEC XBRL | +12.3% | -632.5% | ORGO higher |
| ROA FY2025, SEC XBRL | +6.2% | -51.5% | ORGO higher |
| Debt / equity as of 2026-09-02 | 0.03 | 6.58 | ORGO lower |
| Revenue growth (YoY) as of 2026-09-02 | +12.2% | -10.8% | ORGO higher |
| Revenue CAGR (3y) SEC XBRL | +7.8% | +31.0% | SMTI higher |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-09-02 | 1.53 | 1.09 | |
| 1-year return as of 2026-10-08 close | -69.0% | +8.4% | SMTI higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.